CTOs on the Move

XyloCor

www.xylocor.com

 
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alexander Gaidamaka
 Senior Vice President of Technology, Manufacturing and Quality Profile

Funding

XyloCor raised $17M on 12/06/2018
XyloCor raised $22.6M on 03/22/2021

Similar Companies

C3 Jian Inc

C3 Jian Inc is a Inglewood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Takeda San Francisco

Takeda San Francisco is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CorneaGen

CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.

Hepion Pharmaceuticals

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T

Immusoft

Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming.